Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease by Hall, S et al.
Longitudinal Measurements of Cerebrospinal Fluid
Biomarkers in Parkinson’s Disease
Sara Hall, MD,1,2* Yulia Surova, MD,1,2 Annika €Ohrfelt, PhD,3 the Swedish BioFINDER Study, Kaj Blennow, MD, PhD,3
Henrik Zetterberg, MD, PhD,3,4 and Oskar Hansson, MD, PhD2,5
1Department of Neurology, Ska˚ne University Hospital, Malm€o, Sweden
2Department of Clinical Sciences, Lund University, Malm€o, Sweden
3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology,
the Sahlgrenska Academy at the University of Gothenburg, Gothenburg and M€olndal, Sweden
4University College London Institute of Neurology, London, United Kingdom
5Memory Clinic, Ska˚ne University Hospital, Malm€o, Sweden
ABSTRACT: Object ive: The purpose of this study
was to investigate whether cerebrospinal fluid (CSF) lev-
els of tau, phosphorylated tau, b-amyloid42, a-synuclein,
neurofilament light, and YKL-40 change over time and if
changes correlate with motor progression and/or cogni-
tive decline in patients with PD and controls.
Methods: We included 63 patients with PD (nonde-
mented) and 21 neurologically healthy controls from the
prospective and longitudinal Swedish BioFINDER study,
all of whom had clinical assessments and lumbar punc-
tures at baseline and after 2 years.
Results : CSF tau levels correlated strongly with
a-synuclein. The levels of CSF a-synuclein, tau, phospho-
rylated tau, neurofilament light, and YKL-40, but not
b-amyloid42, increased in CSF over 2 years in PD. No
changes were seen in the control group. Studying
patients with a short disease duration ( 5 years) and
patients with a long disease duration (>5 years) sepa-
rately, a-synuclein and tau only increased in the PD group
with long disease duration. In the PD group, an increase
in phosphorylated tau over 2 years correlated with faster
motor progression and faster cognitive decline. An
increase in YKL-40 over 2 years correlated with faster
cognitive decline.
Conclus ion: CSF biomarkers reflecting Lewy body
pathology and neurodegeneration (a-synuclein), neuronal
degeneration (tau, phosphorylated tau, and neurofilament
light), and inflammation (YKL-40) increase significantly over
2 years in PD. CSF levels of a-synuclein and tau correlate
and remain stable in the early symptomatic phase of PD but
increase in the later phase. We hypothesize that CSF
a-synuclein levels might increase as a result of more intense
neurodegeneration in PD with long disease duration.
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It is important to understand the temporal changes
in biomarkers to improve early diagnosis in PD, but
also to identify biomarkers that could be used in ther-
apeutic trials to evaluate new disease-modifying thera-
pies. Still, few longitudinal cerebrospinal fluid (CSF)
biomarker studies have yet been performed. Many
cross-sectional studies during the past years have eval-
uated the diagnostic potential of a-synuclein (a-syn),
neurofilament light (NFL), tau, phosphorylated tau (P-
tau), and amyloid b (Ab) for PD-related disorders.
CSF levels of a-syn have, when compared with con-
trols, been found to be decreased in patients with PD
as well as in patients with other synucleinopathies, for
example, dementia with Lewy bodies and multiple sys-
tem atrophy.1-5 On the other hand, CSF a-syn shows
a very marked increase in disorders with rapid neuro-
degeneration such as Creutzfeldt-Jakob disease6 and
also a clear increase in Alzheimer’s disease (AD) when
compared with both controls and patients with PD,5
indicating that a-syn levels in CSF reflect neuronal
degeneration. Levels of CSF biomarkers more com-
monly associated with AD, that is, tau, P-tau, and
Ab42, have been found to be normal or slightly
decreased in PD when compared with controls.2,3,5 In
AD, tau and P-tau have been shown to be increased
when compared with controls, whereas Ab42 has been
shown to be decreased when compared with con-
trols.7,8 In patients with PD with dementia, most stud-
ies have shown normal levels of tau and P-tau when
compared with controls and normal or decreased lev-
els of Ab42.
5,9-13 We and another group have previ-
ously shown positive correlations between CSF a-syn
and tau as well as P-tau.3,14 However, this contradicts
the results from Parnetti and colleagues,15,16 who
found negative correlations between a-syn and tau.
NFL (a biomarker for degeneration or injury of large
myelinated axons) has been found to be increased in
atypical parkinsonism when compared with PD.5,17,18
Furthermore, we have previously shown that NFL cor-
relates with disease stage in PD.5 YKL-40, also called
chitinase-3-like 1 is a glycoprotein that is up-regulated
in inflammatory conditions.19 In the brain, YKL-40 is
expressed primarily in microglia and astrocytes.20,21
Some longitudinal studies have investigated the asso-
ciation between baseline CSF biomarkers and subse-
quent disease progression in PD. Lower CSF Ab42 has
been shown to predict the subsequent development of
cognitive decline in nondemented PD patients.14,16,22-
24 Although several studies have shown decreased lev-
els of CSF a-syn in patients with PD,1-5 our group has
shown that increased baseline levels of CSF a-syn
within the PD group predict future progression of
motor symptoms and cognitive decline.14 This con-
firmed previous results showing that increased baseline
levels of a-syn are associated with future decline in
cognitive function in PD patients.25 These results indi-
cate that the association between CSF a-synuclein and
PD is complex, and we have hypothesized that CSF a-
synuclein starts to decrease during the preclinical
stages of PD as a result of intraneuronal accumulation,
but CSF a-syn levels might also reflect neuronal dam-
age with increasing values as the disease progresses.
However, there are yet few studies that have assessed
the longitudinal changes in CSF biomarkers over time
in PD. Zhang and colleagues found that the rate of
change in tau and tau/Ab42 positively correlated with
faster motor progression measured by UPDRS score,
and Stewart and colleagues found a reduction in CSF
a-syn over a follow-up of approximately 2 years, but
this change did not correlate with worsening of motor
symptoms or cognitive decline.25,26
In the present prospective and longitudinal study, we
investigated the CSF levels of tau, P-tau, Ab42, NFL, a-
syn, and YKL-40 both at baseline and after 2 years of
follow-up in neurologically healthy elderly controls and
patients with PD. Our aim was to investigate if there are
changes over time in these CSF biomarker levels. We
also studied if any changes in biomarker levels over
time correlated with faster motor progression and/or
cognitive decline in patients with PD.
Methods
Participants
This prospective and longitudinal study was per-
formed at the Clinic of Neurology, Ska˚ne University
Hospital, Sweden, as part of the Swedish BioFINDER
Study (www.biofinder.se). The study participants are
primarily recruited from the southern region of Sweden
and are followed with repeated neurologic, psychiatric,
and cognitive assessments and collection of CSF and
blood samples under standardized conditions. In this
study, we included 63 patients with PD (nondemented),
of whom 37 had short disease duration ( 5 years dis-
ease duration) and 26 had long disease duration (> 5
years disease duration) who had had lumbar puncture
at baseline and at the 2 year follow-up. Of the patients
with short disease duration, 11 were De Novo. The
patients with PD met the National Institute of
Neurological Disorders and Stroke Diagnostic Criteria
for PD.27 None of the PD patients met criteria for PD
with dementia at baseline.28 We also included 21
neurologically healthy controls with lumbar puncture at
baseline and at the 2 year follow-up. All control
participants underwent cognitive testing and neurologic
examination by a medical doctor, and individuals with
objective cognitive or parkinsonian symptoms were not
included as controls in the present study.
At baseline and at the 2 year follow-up, a thorough
medical history was taken and the patients underwent
extensive testing for both motor symptoms and cogni-
tion. The patients were examined by a physician expe-
rienced in movement disorders and a registered
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research nurse using the UPDRS III, the Hoehn and
Yahr Scale, and the Timed Up and Go test (TUG)
among other scales.29-31 The study participants’ cogni-
tive function was assessed using the Mini Mental State
Examination (MMSE), the Alzheimer’s Disease Assess-
ment Scale (ADAS) items 1 to 3, and the 1-minute
phonetic verbal fluency test or letter fluency test.32-34
All individuals gave written informed consent. The
study procedure was approved by the local ethics com-
mittee at Lund University Sweden and conducted
according to the Helsinki Declaration.
CSF Samples
CSF samples were obtained by lumbar puncture in
the L3/L4 or L4/L5 interspace with patients nonfast-
ing. The samples were collected in polypropylene
tubes and gently mixed to avoid gradient effects. All
samples were centrifuged within 30 minutes at148C
at 2000g for 10 minutes to remove cells and debris and
then stored in aliquots at 2808C pending biochemical
analysis.
CSF Ab42, tau, and P-tau were analyzed using Alz-
Bio3 (Fujirebio, Ghent, Belgium), NFL was analysed
using the NF-light assay (UmanDiagnostics, Umea˚,
Sweden), YKL-40 was analyzed using the Human Chi-
tinase 3-like 1 Quantikine ELISA Kit (R&D, Minne-
apolis, Minnesota), a-syn was analyzed using the
Covance assay (Covance, Dedham, Massachusetts),
and haemoglobin was analyzed with an assay pro-
vided by Bethyl Lab, Inc. (Montgomery, Texas). For
a-syn, only samples with haemoglobin <200 ng/ml
were used; consequently, 4 samples from PD patients
(all PD with long disease duration) and 1 sample from
the controls were excluded, all baseline samples.
For P-tau there were 8 missing in the control group
and 16 missing in the PD group. Baseline and follow-
up CSF samples were always analyzed in the same
batch. All analyses were performed using 1 batch of
reagents by board-certified laboratory technicians who
were blinded to clinical data. Intra-assay coefficients
of variation were below 10%.
Statistics
The statistical analyses were accomplished with
SPSS for Windows, version 22.0 (SPSS Inc., Chicago,
Illinois). To compare demographic and CSF baseline
data between groups, the Mann–Whitney U test was
used for continuous variables. The Pearson chi-
squared test was used to compare proportions. Univar-
iate associations between 2 continuous variables were
analyzed using Pearson’s r (normally distributed varia-
bles) or Spearman’s rho (skewed variables and/or ordi-
nal data). Correlations between CSF biomarkers were
investigated with linear regression to correct for con-
founding factors. To investigate changes in CSF bio-
marker levels over time we used a paired t test, and in
the case of nonnormally distributed data we used Wil-
coxon signed-rank test. Correlations between baseline
data and changes over 2 years in CSF biomarker levels
were investigated with bivariate correlations. Correla-
tions between changes over 2 years in CSF biomarker
levels and changes over 2 years in clinical test scores
as well as correlations with changes in other CSF bio-
markers were then investigated with a linear regres-
sion, adjusting for age and Levodopa equivalent
(LED).
Results
Demographics
Demographics and clinical characteristics of study
participants at baseline and at 2 years are given in Table
1. CSF biomarker levels at baseline and at 2 years are
given in Table 2. There were no gender effects. In the
PD group, age correlated positively with a-syn
(P5 .028, R5 .286), tau (P5 .001, R5 .394), YKL-40
(P< .001, R5 .576), and NFL (P< .001, R5 .517) and
negatively with Ab42 (P5 .037, R52.263). In the con-
trol group, age correlated positively with YKL-40
(P5 .014, R5 .525) and NFL (P5 .002, R5 .643) and
negatively with Ab42 (P5 .023, R52.495). The levels
of NFL, but no other CSF biomarkers, correlated with
disease duration (P5 .027, R52.279). None of the
CSF biomarkers correlated with disease severity as
measured by the Hoehn &Yahr or UPDRS III. In the PD
group, LED correlated with Ab42 (P5 .017, R5 .300),
but not with any of the other CSF biomarkers. In the
PD group as a whole and in the PD group with short
disease duration, but not in the PD group with long dis-
ease duration, there was a significant worsening in the
Hoehn & Yahr score (z522.486, P5 .013 and
z522.366, P5 .018, respectively) and a significant
increase in LED (z523.377, P< .001 and z524.405,
P< .001, respectively) over 2 years. In the PD group
with long disease duration, there was a significant wor-
sening in letter fluency (t245 4.612, P< .001). There
were no significant changes in clinical test scores in the
control group over 2 years.
Correlations Between CSF Biomarkers
at Baseline
In the PD group and in the control group, a-syn corre-
lated with tau (P< .001, b> .84), Ab42 (P< .05,
b> .30), and YKL-40 (P< .001, b> .78), when adjust-
ing for age and also LED in the case of PD. Tau corre-
lated with YKL-40 (P< .03, b> .52) and NFL (P<
.002, b> .39) when adjusting for age and also LED in
the case of PD.
In the PD group but not in the control group, P-tau cor-
related with tau (P5 .001, b5 .440), a-syn (P< .001,
b5 .541), and YKL-40 (P5 .013, b5 .421), adjusting for
age and LED.
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Change Over 2 Years in Levels
of CSF Biomarkers
There were no significant changes over time in CSF
biomarkers in the control group.
After 2 years of follow-up, the PD group exhibited
significantly increased levels of the CSF biomarkers
tau (t62522.570, P5 .013), P-tau (t46522.458, P5
.018), a-syn (t58522.350, P5 .022), NFL (z5
23.769, P< .001), and YKL-40 (t62523.682,
P< .001) when compared with baseline levels (Figure
1 and Supplementary Figure S1).
In the PD patients with short disease duration (5
years; n5 37), there were significantly increased levels
of CSF biomarkers in NFL (z523.079, P5 .002) and
YKL-40 (t36522.675, P5 .011) after 2 years. There
was no significant increase in a-syn or tau levels in the
PD group with short disease duration (Figure 2 and
Supplementary Figure S2). Furthermore, in the PD
patients with mild and unilateral PD symptomatology
(ie, Hoehn &Yahr score of<2; n515) at baseline
only NFL increased significantly over 2 years (z5
22.101, P5 .036).
In the PD patients with long disease duration (> 5
years; n5 26), there were significantly increased levels
of CSF biomarkers in a-syn (z522.192, P5 .028),
tau (z522.437, P5 .015), NFL (z522.210,
TABLE 2. CSF biomarkers at baseline and at 2 years
Control (n5 21) PD total (n563)
PD with short disease
duration (n537)
PD with long disease
duration (n526)
a-Syn at baseline 1975 (758) (1127–4346) 1763 (496) (706–2857) 1718 (479) (1030–2857) 1839 (527) (706–2644)
a-Syn at 2 years 1864 (623) (1119–3643) 1830 (569) (773–3070) 1746 (466) (1141–2986) 1949 (681) (773–3070)
Ab42 at baseline 410 (197) (177–1086) 415 (120) (187–838) 406 (122) (192–838) 428 (118) (187–646)
Ab42 at 2 years 410 (152) (156–664) 434 (153) (144–761) 420 (137) (155–761) 454 (173) (144–760)
Tau at baseline 100 (43) (43–214) 81 (31) (34–178) 82 (35) (34–178) 81 (24) (34–155)
Tau at 2 years 97 (40) (39–185) 86 (34) (35–203) 85 (36) (38–203) 88 (32) (35–181)
P-tau at baseline 50 (18) (29–83) 40 (11) (21–65) 40 (11) (21–65) 40 (10) (23–61)
P-tau at 2 years 58 (25) (27–110) 44 (14) (10–87) 44 (11) (27–76) 45 (17) (10–87)
NFL at baseline 852 (457) (443–2532) 913 (569) (4372–4328) 959 (637) (440–4328) 846 (461) (372–2295)
NFL at 2 years 898 (467) (424–2174) 994 (424) (367–2715) 992 (327) (434–1677) 998 (541) (367–2715)
YKL-40 at baseline 183,515 (60,371) 164,073 (57,190) 170,582 (60,739) 154,809 (51,448)
(100,320–341,183) (47,402–328,160) (47,402–328,160) (86,916–303,987)
YKL-40 at 2 years 187,602 (61,295) 178,964 (68,955) 183,049 (72,223) 173,152 (64,967)
(101,887–357,882) (47,752–350,088) (47,752–350,088) (67,976–334,806)
The data are presented in ng/L as the mean (standard deviation) as well as range (minimum–maximum). For P-tau analyses, 8 values were missing in the con-
trol group and 16 values were missing in the PD group (1 PD with short disease duration and 15 PD with long disease duration) as a result of technical errors.
For a-synuclein (a-syn), only samples with Hb< 200 ng/ml were used, and consequently 4 samples from PD patients (all with long disease duration) and 1
sample from controls were excluded. Amyloid b, Ab; P-tau, phosphorylated tau; NFL, neurofilament light.
TABLE 1. Demographics
Control (n5 21) PD total (n563)
PD with short disease
duration (n5 37)
PD with long disease
duration (n5 26)
Age at baseline 65.7 (6.8) 64.7 (9.4) 65.4 (10) 63.7 (8.6)
Women/Men 13/8 21/42b 14/23 7/19b
Disease duration at baseline NA 5.5 (4.0) 2.7 (1.4) 9.6 (2.9)c
Hoehn & Yahr score at baseline NA 2.0 (0.7) 1.9 (0.7) 2.2 (0.5)
Hoehn & Yahr score at 2 years NA 2.3 (0.7) 2.3 (0.7) 2.3 (0.7)
UPDRS III score at baseline 1.5 (2.2) 19.2 (9.4)a 17.3 (7.6)a 22.0 (11.0)a
UPDRS III score at 2 years 2.2 (2.6) 17.7 (11.7)a 15.7 (11.1) 20.7 (12.2)
MMSE at baseline 28.1 (1.8) 28.5 (1.4) 28.6 (1.3) 28.2 (1.5)
MMSE at 2 years 28.4 (1.5) 28.0 (2.2) 28.1 (1.9) 27.8 (2.6)
Letter S fluency at baseline 16.7 (5.0) 15.5 (5.3) 14.3 (4.2) 17.2 (6.3)d
Letter S fluency at 2 years 16.0 (5.9) 14.4 (6.5) 14.6 (6.2) 14.1 (7.0)
Levodopa equivalent at baseline NA 565 (469) 279 (248) 972 (404)c
Levodopa equivalent at 2 years NA 767 (389) 499 (212) 939 (443)c
The data are presented as mean (standard deviation). NA, not applicable.
Letter fluency was missing in 1 PD patient (with long disease duration).
aP<.001 versus controls.
bP<.05 versus controls.
cP<.001 versus PD with short disease duration.
dP<.05 versus PD with short disease duration.
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P5 .027), and YKL-40 (z522.222, P5 .026) after 2
years (Figure 2 and Supplementary Figure S2). In PD
patients with more severe and bilateral disease (ie,
Hoehn &Yahr score of2; n548) at baseline, levels
of the same CSF biomarkers increased significantly
over 2 years, that is, a-syn, t43522.232, P5 .031;
tau, z522.257, P5 .024; P-tau, t35522.135, P5
.040; NFL, z523.185, P5 .001; and YKL-40, z5
23.241, P5 .001.
Correlations Between Changes in CSF
Biomarkers Over 2 Years in the PD Group
An increase in a-syn levels correlated with increases
in tau (P< .001, b5 .583), P-tau (P5 .002, b5 .470),
and YKL-40 (P< .001, b5 .564) over a 2-year period
in PD. Furthermore, increases in tau levels correlated
with increases in the levels of P-tau (P< .001,
b5 .496), YKL-40 (P5 .001, b5 .401), and NFL
(P5 .007, b5 .347). Increases in P-tau correlated with
increases in YKL-40 (P5 .012, b5 .375), all adjusted
for age and LED (Supplementary Table S1).
Correlations Between Baseline CSF Data and
Changes in CSF Biomarkers Over 2 Years
Higher levels of P-tau at baseline correlated with
decreases in Ab42 over 2 years (P5 .001, R52.454).
None of the other CSF biomarkers at baseline pre-
dicted change in CSF biomarkers over 2 years.
Correlations Between Changes in CSF
Biomarkers and Changes in Clinical Test
Scores Over 2 Years in the PD Group
An increase in P-tau over 2 years in the whole PD
group correlated with worsening of motor symptoms
over 2 years as measured by the UPDRS III (P5 .048,
b5 .292), but not TUG, and with worsening of cogni-
tive executive function as measured by letter fluency
(P5 .002, b52.440), but not MMSE, when adjusting
for age and LED. An increase in YKL-40 over 2 years
correlated with worsening of cognitive function as
measured by letter fluency (P5 .032, b52.276), but
not MMSE in PD when adjusting for age and LED
(Figure 3). Changes in CSF levels of a-syn, tau, and
NFL over 2 years did not correlate with changes in
motor symptoms (as measured by UPDRS III or TUG)
or cognitive function (as measured by letter fluency or
MMSE) when adjusting for age and LED.
Discussion
In this prospective longitudinal study, we showed
that levels of the CSF biomarkers tau, P-tau, a-syn,
NFL, and YKL-40 increase significantly over a period
of 2 years selectively in the PD group, whereas control
individuals had stable levels. Furthermore, we found
that a-syn and tau levels are stable early in the symp-
tomatic disease process, but they increase over time
later in the disease course and in more severe disease,
with CSF levels of a-syn and tau correlating with each
other. We also found that a more rapid increase in
CSF levels of P-tau correlates with faster motor pro-
gression as well as cognitive decline as measured by
the UPDRS III and letter fluency, respectively, and
that a more rapid increase in CSF levels of YKL-40 is
associated with faster cognitive decline as measured by
letter fluency.
Originally, CSF a-syn tests were developed with the
hope that they would reflect Lewy body pathology.
Indeed, most synucleinopathies show slightly reduced
CSF levels of a-syn when compared with the levels
FIG. 2. Percent change in CSF levels of a-synuclein (a-syn) in PD with
short and long disease duration over 2 years. Levels of CSF a-syn
increase in the PD group with long disease duration over 2 years but not
in the PD group with long disease duration. Scatter dots of change in
percentages in CSF levels of a-syn in PD with short and long disease
durations. Lines represent means and standard deviations.
FIG. 1. Percent change in CSF levels of amyloid b42 (Ab42), a-
synuclein (a-syn), tau, phosphorylated tau (P-tau), neurofilament light
(NFL), and YKL-40 over 2 years. Scatter dots of change in percen-
tages in CSF levels of Ab42, tau, P-tau, a-syn, NFL, and YKL-40 over
2 years. Lines represent means and standard deviations. One data
point for P-tau at 200% and 1 data point for NFL at 276% are outside
the axis limit.
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seen in neurologically normal control individuals. How-
ever, this reduction is subtle when compared with the
reduced CSF Ab42 levels seen in cerebral b-amyloidoses
such as AD and dementia with Lewy bodies, and it is
presently unclear exactly what CSF a-syn concentra-
tions represent. In the present study, CSF a-syn levels
correlated strongly with CSF tau, an established marker
of neurodegeneration.35 Although levels of a-syn are
moderately decreased in synucleinopathies, emerging
evidence suggests that increased CSF levels of the pre-
synaptic protein a-syn are associated with more intense
neurodegeneration2,4-6 as well as a worse prognostic
outcome in PD.14,25 However, it is still unclear why the
levels of CSF a-syn do not seem to correlate with dis-
ease duration in cross-sectional analyses,4,14,15 but dis-
ease duration is a retrospective and not very precise
measure when used on its own.
One study has previously found a reduction in CSF a-
syn during a follow-up of approximately 2 years in PD
with short disease duration.25 We found that both CSF
a-syn and tau mainly increase during the later stages of
the disease as well as in the more severe phases of PD,
when the neurodegeneration is probably more wide-
spread. These results indicate that the association
between CSF a-syn and PD is complex not only reflect-
ing the disease itself but also the disease stage. We
therefore hypothesize that the CSF levels of a-syn are
bimodal over time and start to decrease early, probably
in the preclinical stage of the disease process relating to
intracellular accumulation. However, CSF a-syn levels
might also reflect neuronal damage with increasing val-
ues as the disease progresses, which is in concordance
with previous studies showing that CSF a-syn is
increased in neurodegenerative disorders, including AD
and Creutzfeldt-Jakob disease.2,4-6 This fact could help
explain the variable association of CSF a-syn levels
with PD across studies.1
We found that the increase in the CSF levels of P-
tau is linked to not only more rapid progression
regarding cognitive executive function as measured by
letter fluency but also more rapid motor progression
as measured by the UPDRS III. CSF P-tau is believed
to reflect tau pathology. In postmortem studies, the
tau protein has been found in Lewy bodies.36 In
genomewide associations studies the MAPT gene has
been linked to PD, and risk alleles of MAPT have
been associated with parkinsonism.37,38 Furthermore,
a-syn in both mouse and human models has been
shown to contribute to the phosphorylation of
tau.39,40 Several studies show slightly decreased levels
of tau in PD when compared with controls.2,3,5 The
rate of change of tau has been shown to be associated
with motor progression.26 Thus, there is evidence that
tau plays a role in the pathophysiology of PD. We
have previously shown that P-tau at baseline is associ-
ated with faster motor progression, and findings in the
present study show that the rate of increase in P-tau is
associated with faster motor progression.14 We thus
confirm the importance of tau pathology in PD and its
role in disease progression. We hypothesize that a
more aggressive disease, as one expects later on in the
disease process, leads to increased levels of tau, a
FIG. 3. Correlations of changes CSF P-tau with change in UPDRS III
and letter fluency and CSF YKL-40 with change in letter fluency over
2 years. Correlations of change in CSF levels of P-tau with change in
UPDRS III (A) and letter fluency (B) in the PD group. Correlations of
change in CSF levels of YKL-40 with change in letter fluency (C) in the
PD group. Solid line indicates a linear regression, and dotted lines are
95% confidence intervals.
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marker of neurodegeneration as well as an increased
release of a-syn, a protein localized in the presynaptic
nerve terminal. This in turn could lead to a greater
phosphorylation of tau, which in turn might aggravate
the disease progression even further.
We have previously shown that NFL is increased in
PD patients with a more advanced disease stage.5 NFL
is a marker of the degeneration of large myelinated
axons and is thus a marker for neurodegeneration.
This is consistent with the result in the present study
showing an increase in NFL over time in PD patients
but not in controls.
Inflammation has also been implicated in the patho-
genesis of PD.41 In this study, we show that YKL-40
increases over time in PD (with short as well as long
disease duration) and that this increase correlates with
faster cognitive decline as measured by letter fluency.
In the brain, YKL-40 is expressed in astrocytes and
microglia, both associated with inflammation.20,21
YKL-40 has been found to be expressed in both acute
neurological disorders and chronic neurological disor-
ders, including traumatic brain injury, stroke, multiple
sclerosis, amyotrophic lateral sclerosis, and AD.42,43
In one positron emission tomography study on PD
patients, evidence of activated microglia was found in
the pons, basal ganglia, and frontal and temporal cort-
ical regions.44 Microglial activation has been shown to
correlate positively with severity of motor symp-
toms.45 This is in line with the present data that
shows that increasing levels of YKL-40 are associated
with a worsening of cognitive function in PD. YKL-40
might consequently be a possible marker in therapeu-
tic trials, especially if immunomodulating therapies
were to be studied.
The increase in CSF levels of tau, P-tau, a-syn,
NFL, and YKL-40 were modest but significant. How-
ever, there was substantial variability in the longitudi-
nal changes in the CSF levels of the biomarkers
between different individual patients, which may
reduce the clinical usefulness of these findings. Natu-
rally, there are also many potential preanalytical con-
founders that might affect the measured CSF
biomarkers, even though lumbar puncture was per-
formed under standardized conditions. Therefore, the
present results need to be replicated in a larger cohort.
Another limitation might be that even though we have
taken great care to follow the diagnostic criteria, a
definite diagnosis in PD requires neuropathology. Fur-
thermore, the patients were examined in the ON state,
which may reduce the reliability of the UPDRS III as a
measure of disease severity over time. Also, with all of
the clinical rating scales used in this study (possibly
with the exception of Hoehn & Yahr), the score is a
snapshot in time. Finally, the follow-up period of the
present study was relatively short. PD is a disease that
develops over many years and in that scope, 2 years is
not long enough to draw any definite conclusions
regarding long-term changes in CSF biomarkers. Thus,
studies with a longer follow-up time are needed, and
we are currently collecting CSF biomarker data from
4 and 6 years of follow-up. Also, to give further
insight in the role of a-syn in the pathophysiology of
PD, it would be important in future studies to study
changes in oligomeric, phosphorylated, and truncated
forms of a-syn as well as total a-syn.
In conclusion, CSF biomarkers reflecting Lewy body
pathology (a-syn), neuronal degeneration (tau, P-tau,
NFL), and inflammation (YKL-40) increase moder-
ately, but significantly, over 2 years in PD. CSF levels
of a-syn and tau remain stable in the early sympto-
matic phase of PD but increase in the later phase. We
hypothesize that CSF a-syn levels might be a reflection
of a more intense neurodegeneration in PD with long
disease duration. To our knowledge, these new find-
ings may in the future be of use in both group stratifi-
cations as well as monitoring in clinical trials.
However, the results need to be validated in future
studies.
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